The FDA is warning healthcare professionals and consumers that filling their prescriptions abroad may have adverse health consequences because of confusion with drug brand names that could inadvertently lead consumers to take the wrong medication for their condition. An FDA investigation has found that many foreign medications, although marketed under the same or similar-sounding brand names as those in the U.S., contain different active ingredients than domestic drugs do. Taking a different active ingredient may not help, and may even harm, the users. For more information, visit http://www.fda.gov/oc/opacom/reports/confusingnames.html.
Mental Health and CBD: What's the Latest Info
October 27th 2022Drug Topics® is joined by Dr. Alex Capano, Chief Science Officer at Ananda Professional to discuss what CBD is used for mental health, where research should go next, and how to ensure that patients are getting effective CBD products.
Promoting Health Equity and Achieving Pharmacoequity to Ensure Medication Access for All
March 27th 2023Speakers at the 2023 virtual Value-Based Insurance Design Summit discussed government programs and company initiatives to advance health equity, as well as the role of research and advocacy to achieve pharmacoequity.
2 Clarke Drive
Cranbury, NJ 08512